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INTRODUCTION
Department of Medicine, Lehigh Valley Health Network, Allentown, Pennsylvania
•  Considered to be a rare culprit of acute mental status changes, autoimmune encephalitis 
accounts for only 4% of encephalitis cases1
•  The presentation of Anti-AMPA-R encephalitis is acute in nature and symptomatology 
consists of psychiatric symptoms, behavioral abnormalities and movement disorders
•  Women over the age of 50 with known autoimmune disorders have been most 
commonly affected 
•  At present, 58% of women and 23% of men who develop this pathologic process are 
found to have an underlying malignancy2
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CASE PRESENTATION
•  A 60 year old female with a history of rheumatoid arthritis and depression presented 
with a one-month history of altered mental status, abnormal behavior and unsteady gait
•  Presenting to an outside hospital, she underwent metabolic, infectious, and 
neuroimaging studies that were unremarkable. It was suspected that she had either a 
rapidly progressive dementia or a brief psychotic disorder triggered by severe depression
•  Her mental status did not improve over a 15-day hospital course and she was 
transferred to our facility. On presentation the patient was not oriented to person place or 
time, was writhing, moaning and completely non verbal.
•  Differentials included CJD, Vasculitis, and paraneoplastic / autoimmune encephalitis. 
Diagnostic studies returned showing positivity for Anti-AMPA-R antibodies, indicating the 
patient had a rare form of autoimmune encephalitis. Extensive work up for underlying 
malignancy was negative
•  The patient made significant improvement with plasma exchange therapy, 
cyclophosphamide and steroids. Her mental status and behavior returned to baseline and 
she was discharged in stable condition
TREATMENT
•  Treatment is largely based on the evaluation of case reports and case series with the 
majority of approaches revolving around combined therapies. 
•  Immunotherapy with either corticosteroids alone or in conjunction with IV 
immunoglobulin or plasma exchange is the mainstay of therapy4,5
•  Second line therapies with rituximab, cyclophosphamide, or combined approach are 
possibilities for those who fail to improve within 4 weeks of immunotherapy4,5
•  It should also be noted that given a significant association with primary tumor 
diagnoses, tumor removal is suggested and has lead to a reduction of antibody levels4,5
DISCUSSION
•  This case in combination with review of several case series in literature suggests that 
the detection of AMPA-R antibodies be considered in patients, particularly women, 
older than 50 years who present not only with limbic encephalitis but also with rapidly 
progressive abnormal behaviors resembling acute psychosis1
•  This patient’s history of a previously diagnosed autoimmune disease should also have 
prompted consideration. Literature suggests that up to 50% of patients diagnosed 
with AMPA-R Ab positive autoimmune encephalitis had history of another systemic 
autoimmune disease2
•  Early detection is crucial due to the high association AMPA-R Ab positive autoimmune 
encephalitis has with underlying malignancy.  An underlying tumor was discovered in 
64% of patients in a case series of 22 patients2   
•  Patients without malignancy tend to respond very well to immunotherapy; however, 
close follow up is indicated due to a relapse rate of up to 50% and diagnosis of a 
primary tumor has occurred during relapses2,3
•  Overall, the prognosis for this patient is very favorable with literature showing a 100% 
5 year survival in patients without underlying malignancy compared with a 50% 5 year 
survival in those with underlying malignancy2
